Ligand Pharmaceuticals Incorporated (LGND) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Ligand Pharmaceuticals Incorporated

NASDAQ | LGND

103.11

USD

-5.62 (-5.17%)

AT CLOSE (AS OF Apr 3, 2025)

$2.1B

MARKET CAP

P/E Ratio

-0.22

EPS

$130

52 Week High

$68

52 Week Low

LIFE SCIENCES

Sector

LGND Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

LGND Technicals

Tags:

LGND Earnings

Yearly Income Statement (As of Dec 31, 2023)

Field	Value (USD)
Gross Profit	$36M
Total Revenue	$133M
Cost Of Revenue	$97M
Costof Goods And Services Sold	$44M
Operating Income	$12M
Selling General And Administrative	$53M
Research And Development	$25M
Operating Expenses	$172M
Investment Income Net	$7.7M
Net Interest Income	-$656K
Interest Income	$7M
Interest Expense	$656K
Non Interest Income	$134M
Other Non Operating Income	-$2M
Depreciation	$2.9M
Depreciation And Amortization	$37M
Income Before Tax	$62M
Income Tax Expense	$9.8M
Interest And Debt Expense	$656K
Net Income From Continuing Operations	$54M
Comprehensive Income Net Of Tax	$52M
Ebit	$63M
Ebitda	$102M
Net Income	$52M

Revenue & Profitability

Earnings Performance

LGND Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2023)

Field	Value (USD)
Total Assets	$787M
Total Current Assets	$237M
Cash And Cash Equivalents At Carrying Value	$23M
Cash And Short Term Investments	$170M
Inventory	$24M
Current Net Receivables	$39M
Total Non Current Assets	$447M
Property Plant Equipment	$16M
Accumulated Depreciation Amortization Ppe	$6.7M
Intangible Assets	$403M
Intangible Assets Excluding Goodwill	$300M
Goodwill	$103M
Investments	$232M
Long Term Investments	$13M
Short Term Investments	$147M
Other Current Assets	$3.8M
Other Non Current Assets	$6.4M
Total Liabilities	$86M
Total Current Liabilities	$17M
Current Accounts Payable	$2.4M
Deferred Revenue	$2.7M
Current Debt	$7K
Short Term Debt	$410K
Total Non Current Liabilities	$67M
Capital Lease Obligations	$19K
Long Term Debt	-
Current Long Term Debt	$0
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$6.2M
Other Current Liabilities	$13M
Other Non Current Liabilities	$28M
Total Shareholder Equity	$701M
Treasury Stock	-
Retained Earnings	$503M
Common Stock	$18K
Common Stock Shares Outstanding	$18M

yearly Cash Flow (As of Dec 31, 2023)

Field	Value (USD)
Operating Cashflow	$50M
Payments For Operating Activities	$11M
Proceeds From Operating Activities	-
Change In Operating Liabilities	-$3.2M
Change In Operating Assets	$8.6M
Depreciation Depletion And Amortization	$37M
Capital Expenditures	$3.5M
Change In Receivables	$4.4M
Change In Inventory	$11M
Profit Loss	$54M
Cashflow From Investment	-$12M
Cashflow From Financing	-$60M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	$0
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	$22M
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	$52M

yearly Income Statement (As of Dec 31, 2023)

Field	Value (USD)
Gross Profit	$36M
Total Revenue	$133M
Cost Of Revenue	$97M
Costof Goods And Services Sold	$44M
Operating Income	$12M
Selling General And Administrative	$53M
Research And Development	$25M
Operating Expenses	$172M
Investment Income Net	$7.7M
Net Interest Income	-$656K
Interest Income	$7M
Interest Expense	$656K
Non Interest Income	$134M
Other Non Operating Income	-$2M
Depreciation	$2.9M
Depreciation And Amortization	$37M
Income Before Tax	$62M
Income Tax Expense	$9.8M
Interest And Debt Expense	$656K
Net Income From Continuing Operations	$54M
Comprehensive Income Net Of Tax	$52M
Ebit	$63M
Ebitda	$102M
Net Income	$52M

Dividends

Field	Value
Ex Dividend Date	2010-07-02
Declaration Date	None
Record Date	None
Payment Date	None
Amount	0.08

LGND Profile

Ligand Pharmaceuticals Incorporated Profile

Sector: LIFE SCIENCES

Industry: PHARMACEUTICAL PREPARATIONS

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.

Most Active

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.02	9.42%	-	776,312,724
NVDA	$101.80	-7.81%	$2.68T	338,769,412
INTC	$22.43	2.05%	$95.85B	242,972,129
F	$9.55	-5.96%	$39.53B	213,326,329
LCID	$2.32	-3.33%	$7.67B	211,931,403

See more →

Symbol	Price	Change %	Market Cap	Volume
JNJ	$159.81	2.86%	$399.65B	13,235,689
PG	$172.39	1.71%	$399.61B	9,393,270
ABBV	$201.64	-1.73%	$364.89B	7,580,327
NVO	$67.12	-1.65%	$308.32B	8,797,694
AZN	$73.92	2.35%	$225.70B	7,926,952

See more →

Top Gainers

Symbol	Price	Change %	Market Cap	Volume
VCIG	$5.99	1,796.17%	$744.62K	310,904
MRM	$0.69	87.76%	$2.91M	54,062,078
PTIX	$0.42	84.14%	$4.04M	177,332,811
OSRH	$2.47	68.03%	$40.06M	89,499,750
OMQS	$0.06	62.16%	$1.50M	59,659

See more →

Top Losers

Symbol	Price	Change %	Market Cap	Volume
ALDX	$1.42	-73.33%	$326.91M	21,941,899
RFAC	$2.70	-68.60%	$8.44M	605,339
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
ICCT	$2.07	-56.14%	$9.78M	12,637,345